A jurisdictional primer
A concise view of the legal frameworks that shape discussion of Trevor Millar, Ambio, cross-border ibogaine practice, research, and commercial provision.
01 / Scope
For people interested in Trevor Millar and the ibogaine clinic question, the first distinction is between what a jurisdiction permits, what it studies, and what it regulates as a commercial service. Those categories can overlap, but they are not interchangeable.
This page follows the wider Trevor Millar and the ibogaine clinic question through that lens: Canada, Mexico, the United States, and the European Union each present different legal conditions, oversight structures, and cross-border implications.
02 / Terms that matter
03 / Canada and cross-border decisions
Ibogaine was added to Canada’s Controlled Drugs and Substances Act schedules in 2017. Health Canada’s ibogaine information page describes the substance as controlled and notes that possession, trafficking, production, and import or export can require authorization.
For the Trevor Millar and Ambio context, that policy shift matters because a Canadian connection does not settle where a service can be offered or how a cross-border arrangement is governed. It can instead make location, sourcing, marketing, records, and the applicable local rules central questions. The site’s information guides distinguish those regulatory questions from any claim about treatment suitability.
04 / Four frameworks
These short descriptions are a practical orientation, not legal advice. Regulation can change by country, state, province, municipality, authority, activity, and time.
Federal controlled-substance rules are a baseline. Provincial professional regulation and other operating obligations may also matter where health-related services are involved. The 2017 scheduling change is a key reference point for Canadian-facing activity.
Mexico is often discussed in relation to cross-border provision, but a destination-country narrative should not erase the importance of local law, facility obligations, import rules, and the limits of any representation made to prospective visitors.
Ibogaine is a Schedule I controlled substance under federal law. The DEA’s scheduling overview explains that Schedule I substances face the highest level of federal control; this is separate from an FDA research authorization.
There is no single EU-wide operating permission for commercial ibogaine clinics. Member-state drug controls, medicines rules, professional standards, and cross-border care rules remain relevant, so country-level review is essential.
05 / Policy markers
Dates are useful for locating public statements and legal contexts, not for inferring authorization across borders. They help place Ambio and Millar-related discussion within the rules then in force.
Federal control of ibogaine developed within the U.S. controlled-substances framework. Its present Schedule I status is the starting point for any U.S. commercial-provision question.
Canada scheduled ibogaine under the Controlled Drugs and Substances Act, changing the federal legal context for possession and supply. This is a central source pointer when considering Canadian links to later clinic activity.
In the U.S., an Investigational New Drug application can support human research under a defined protocol. It does not turn investigational work into general commercial availability.
06 / Clarifications
No. Regulatory status describes the legal framework for possession, research, manufacturing, or provision in a jurisdiction. It does not by itself establish safety, suitability, or medical efficacy. The safety and risk profile separates those questions for people reviewing this topic.
An IND is the FDA mechanism that can permit a sponsor to study an investigational drug in humans under a protocol. It is distinct from commercial approval and does not authorize ordinary clinic provision. That distinction matters when research language appears alongside clinic language.
Traditional cultural contexts and commercial services can be governed by different histories, laws, permissions, and oversight structures. The general background on ibogaine should not be used to collapse those settings into one legal category.
Independent information
When assessing claims connected to Trevor Millar, Ambio, or a named setting, ask which jurisdiction applies, what activity is being described, what date is relevant, and whether the claim concerns research, professional practice, or commercial provision.